Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV Genotype 1b (GARNET)
NCT02582632Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of ombitasvir, paritaprevir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Nov 2015; status: completed.
02
Drugs
ombitasvirparitaprevirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02582632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582632.